is semaglutide approved by fda approves higher dose of Wegovy to increase patient weight loss FDA Approves Semaglutide for MASH

Here we report the engineering and preclinical development of a bimodal molecule that integrates NMDA receptor antagonism with glucagon-like peptide-1 (GLP-1) receptor agonism to effectively reverse obesity, hyperglycaemia and dyslipidaemia in rodent models of metabolic disease

Rev Gastroenterol Mx

Inhibition of miR-29b suppresses MAPK signaling pathway through targeting SPRY1 in atherosclerosis

Pancreatic safety of once-weekly dulaglutide in Chinese patients with type 2 diabetes mellitus: Subgroup analysis by potential influencing factors

Stay Informed Monitor emerging clinical trial data for CagriSema and other combinations Follow regulatory developments as new therapies approach approval Engage with continuing education on peptide mechanisms and applications 2